Literature DB >> 16932873

Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study.

S de Lusignan1, J van Vlymen, N Hague, N Dhoul.   

Abstract

BACKGROUND: National guidelines recommend bisphosphonates for secondary prevention of osteoporotic fractures; however, poor compliance may result in sub-optimal prevention.
OBJECTIVE: This study reports the feasibility of using GP electronic records to identify poorly compliant post-menopausal women who may be at increased risk of fragility fractures.
DESIGN: Cross-sectional study of general practice computer records.
SUBJECTS: Women over 45 years, registered in 29 practices across England with a total population of approximately 200,000.
METHODS: MIQUEST (Morbidity Information Query and Export Syntax) a data extraction application was used to extract prescription, diagnostic data and probable fragility fractures (hip, vertebral, wrist). All women >45 years who received a first prescription for a weekly bisphosphonate (alendronate or risedronate) at least a year before data extraction were identified. Each record was examined to determine the number of days of prescribed treatment.
RESULTS: Of 97992 registered women, 44% (42734) were >45 years. Prevalence of likely fragility fractures in women over 45 was 5.1% (2195/42734). 3.0% (1286/42734, mean age 72 years) received a prescription for a bisphosphonate in the 360 day period prior to data extraction with a median duration of treatment of 267 days. 45% (584/1286) received prescriptions covering >288/360 days (Medicine Possession Ratio >80%); 13% (161/1286) collected prescriptions covering >360 days. In those prescribed bisphosphonates, 23% (294/1286) had a likely fragility fracture.
CONCLUSIONS: Women >45 years with probable fragility fractures are more likely to be prescribed bisphosphonates, though less than half will be actually taking them as prescribed. GPs should use computer technology to identify poorly compliant patients who are unnecessarily at risk of fracture.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932873     DOI: 10.1007/s00198-006-0188-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  24 in total

1.  Ensuring the Quality of Aggregated General Practice Data: Lessons from the Primary Care Data Quality Programme (PCDQ).

Authors:  Jeremy van Vlymen; Simon de Lusignan; Nigel Hague; Tom Chan; Billy Dzregah
Journal:  Stud Health Technol Inform       Date:  2005

2.  A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data.

Authors:  Jeremy van Vlymen; Simon de Lusignan
Journal:  Inform Prim Care       Date:  2005

3.  Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Authors:  H A Pols; D Felsenberg; D A Hanley; J Stepán; M Muñoz-Torres; T J Wilkin; G Qin-sheng; A M Galich; K Vandormael; A J Yates; B Stych
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

4.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

Review 5.  Epidemiology and outcomes of osteoporotic fractures.

Authors:  Steven R Cummings; L Joseph Melton
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

6.  Quality and variability of osteoporosis data in general practice computer records: implications for disease registers.

Authors:  S de Lusignan; T Chan; O Wood; N Hague; T Valentin; J Van Vlymen
Journal:  Public Health       Date:  2005-09       Impact factor: 2.427

7.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

Authors:  Pierre D Delmas; Kristine E Ensrud; Jonathan D Adachi; Kristine D Harper; Somnath Sarkar; Carlo Gennari; Jean-Yves Reginster; Huibert A P Pols; Robert R Recker; Steven T Harris; Wentao Wu; Harry K Genant; Dennis M Black; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

8.  Prevalence of osteoporotic bone mineral density at the hip in Britain differs substantially from the US over 50 years of age: implications for clinical densitometry.

Authors:  G Holt; K T Khaw; D M Reid; J E Compston; A Bhalla; A D Woolf; N J Crabtree; N Dalzell; B Wardley-Smith; M Lunt; J Reeve
Journal:  Br J Radiol       Date:  2002-09       Impact factor: 3.039

9.  Compliance with drug therapies for the treatment and prevention of osteoporosis.

Authors:  Jeffrey S McCombs; Patrick Thiebaud; Connie McLaughlin-Miley; Jinhai Shi
Journal:  Maturitas       Date:  2004-07-15       Impact factor: 4.342

10.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

View more
  5 in total

Review 1.  Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource.

Authors:  Tim Williams; Tjeerd van Staa; Shivani Puri; Susan Eaton
Journal:  Ther Adv Drug Saf       Date:  2012-04

2.  Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data.

Authors:  Joanne LaFleur; Carrie McAdam-Marx; Stephen S Alder; Xiaoming Sheng; Carl V Asche; Jonathan Nebeker; Diana I Brixner; Stuart L Silverman
Journal:  J Bone Miner Metab       Date:  2010-08-06       Impact factor: 2.626

3.  Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Authors:  O Ström; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2012-12-07       Impact factor: 4.507

Review 4.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

5.  Improving detection and treatment of osteoporosis: redesigning care using the electronic medical record and shared medical appointments.

Authors:  W T Ayoub; E D Newman; M A Blosky; W F Stewart; G C Wood
Journal:  Osteoporos Int       Date:  2008-05-21       Impact factor: 4.507

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.